DR. PAUL E. CAMPBELL

Plain English
This study focused on a condition called systemic sclerosis (SSc), an autoimmune disease that leads to thickening and scarring of the skin. Researchers found that certain proteins (CD13 and B1 receptor) were more active in the skin of patients with a severe form of SSc, contributing to excessive scar formation. By blocking the B1 receptor, they were able to reduce the fibrosis-related responses in lab tests and in mice, showing that this approach could be a new way to treat SSc. Who this helps: This helps patients with systemic sclerosis and their doctors by potentially offering a new treatment option.

Plain English
This study looked at a substance called soluble CD13 (sCD13), which is produced during COVID-19 infections. Researchers found that patients with severe COVID-19 had much higher levels of sCD13, and this was linked to increased inflammation and complications. Specifically, elevated sCD13 levels were associated with heightened immune response processes that lead to blood vessel stress and clot formation. Who this helps: This research benefits COVID-19 patients and doctors by highlighting possible targets for new treatments.

Plain English
This study investigated how a special antibody, UMCD6, affects immune cells that fight cancer. Researchers found that UMCD6 helps these immune cells, particularly natural killer (NK) cells and certain T cells, become more effective at killing cancer cells in mice with breast and prostate cancer, leading to improved survival rates. Specifically, treated mice had more powerful immune cells that were better positioned to attack tumors compared to those treated with a standard antibody. Who this helps: This benefits cancer patients by potentially improving treatments that enhance their immune responses to tumors.

Plain English
This study looked at a protein called MCP-1/CCL2, which attracts certain immune cells and is found in high levels in the joints of patients with rheumatoid arthritis. Researchers discovered that when MCP-1/CCL2 is altered by a process called citrullination, it usually gets partially broken down, but if it is properly modified with sugar molecules (glycosylation), it stays intact and can be more effectively used in lab tests. This finding is important because it could improve the way we measure and understand the role of MCP-1/CCL2 in diseases like rheumatoid arthritis. Who this helps: Patients with rheumatoid arthritis and the doctors treating them.

Plain English
This study looked at a specific way to boost the immune system's ability to fight cancer by focusing on a molecule called CD6. Researchers found that using an antibody (UMCD6) to block the interaction between CD6 and a protein found on many cancer cells (CD318) led to better survival rates in mice with breast and prostate cancer. In these mice, more immune cells that attack tumors, like NK and CD8+ T cells, were present and more active compared to those that didn’t receive the treatment. Who this helps: This benefits cancer patients by potentially improving treatment outcomes.

Plain English
This study looked at how blocking certain proteins called bromodomain extraterminal (BET) proteins can help reduce skin thickening in a condition known as scleroderma. The researchers found that using a drug called JQ1 to inhibit these proteins led to a significant reduction in fibrosis in lab animals and skin cells from scleroderma patients. Specifically, they observed changes in gene activity that affect cell growth and calcium levels, which are important for managing tissue fibrosis. Who this helps: This benefits patients with scleroderma by offering potential new treatment options.

Plain English
Researchers discovered that a protein called CD13, which leaks into the bloodstream, causes inflammatory arthritis by activating a receptor called B1R found on joint cells. They confirmed this by showing that blocking B1R with drugs stopped the inflammation in multiple types of arthritis in mice and in human joint tissue samples. This matters because B1R could be a new drug target to treat rheumatoid arthritis and other inflammatory diseases by preventing CD13 from triggering joint inflammation.

Plain English
This research studied a new cancer treatment involving a specific antibody called UMCD6 that targets a protein known as CD6. The findings showed that UMCD6 significantly improved the ability of immune cells to kill breast, lung, and prostate cancer cells, leading to more effective cancer cell death than traditional treatments that block certain immune checkpoints. This is important because it not only enhances cancer killing but also helps control autoimmune responses, making it a promising new approach for cancer immunotherapy. Who this helps: This benefits cancer patients and doctors seeking more effective treatment options.

Plain English
This study looked at the tail tube of the bacteriophage lambda, a virus that infects bacteria. Researchers discovered that this tail tube is made up of a protein that has two different parts, one of which helps to maintain its flexible structure while still being strong enough to deliver DNA into bacteria. They found that specific interactions within the protein are crucial for making the tail tube both sturdy and adaptable, highlighting how different viruses can have similar components but function differently. Who this helps: This benefits researchers and scientists studying viral infections and potential treatments.

Plain English
Researchers studied the role of a protein called CD6 in a mouse model of rheumatoid arthritis (RA) to understand how it affects inflammation. They found that mice lacking CD6 had less joint damage and lower levels of inflammatory proteins compared to normal mice, indicating that targeting CD6 might help reduce arthritis symptoms. Specifically, reduced inflammation and joint damage were observed in CD6-deficient mice, and treatment with an antibody against human CD6 also lowered joint inflammation. Who this helps: This research helps patients with rheumatoid arthritis and doctors looking for new treatment options.

Plain English
This research studied how different immune cells can kill cancer cells using a special imaging system called IncuCyte. The scientists created a new, cost-effective way to label cancer cells with a red fluorescent protein, enabling them to track cell death and survival in real time. This method allows for easier and more diverse testing of immune responses against various types of cancer, which can lead to better treatments. Who this helps: This helps researchers and doctors working to develop new cancer immunotherapies.

Plain English
This study focused on developing a new type of drug that can potentially help treat scleroderma, a condition that causes skin and connective tissue to become thick and stiff. Researchers discovered a new compound that was very effective at blocking a specific process in cells linked to this disease, achieving a strong impact at very low doses. The best candidates in this study significantly lowered fibrosis-related gene activity and helped reduce skin thickening in mouse models. Who this helps: This helps patients with scleroderma and doctors seeking new treatment options.

Plain English
This study focused on a series of compounds, specifically CCG-1423 and CCG-203971, which were tested for their ability to prevent the spread of melanoma and reduce scarring caused by a drug called bleomycin. Researchers discovered that these compounds work by targeting a protein called pirin, which is involved in cellular processes related to fibrosis and cancer. They found that when pirin is inhibited, it can help reduce gene expression linked to these diseases, and a new compound, CCG-257081, effectively prevents skin scarring in their tests. Who this helps: This benefits patients with melanoma and those suffering from fibrosis.

Plain English
Researchers found that a protein called ID-1 becomes modified in rheumatoid arthritis patients' joints in a way that triggers the immune system to attack it—this modification doesn't happen in healthy people. When they removed ID-1 from arthritis cells in the lab, the cells produced more inflammatory chemicals and grew less, suggesting ID-1 normally helps control inflammation in the joint. ID-1 levels in patients' blood dropped after they received anti-inflammatory treatment, and three specific spots on the protein are responsible for triggering the immune attack. **Why it matters:** This discovery identifies a new target that the immune system mistakenly attacks in rheumatoid arthritis, which could help explain why the disease develops and might lead to better treatments or diagnostic tests.

Plain English
Researchers found that a protein called CD13, which is released into fluid in inflamed joints, promotes the growth of new blood vessels and attracts immune cells to the joint—both hallmarks of rheumatoid arthritis. The protein works through its structure rather than its enzymatic function, and when injected into mouse knees, it triggered joint swelling and inflammation. This discovery suggests that blocking CD13 could be a new way to treat rheumatoid arthritis and other inflammatory joint diseases.

Plain English
This study looked at a protein called galectin-9 (Gal-9) to understand its role in creating new blood vessels and causing inflammation in arthritis. The researchers found that Gal-9 increased the movement of blood vessel cells by 50% and led to more blood vessel formation in lab tests and a significant rise in immune cell movement when injected into mouse knees. These findings matter because they show how Gal-9 might contribute to arthritis and other inflammatory diseases, offering potential new targets for treatment. Who this helps: This helps patients with rheumatoid arthritis and other inflammatory conditions.

Plain English
This study looked at a new drug called Takinib, which blocks a protein (TAK1) that plays a role in how cells respond to tumor necrosis factor alpha (TNF-α). Researchers found that Takinib can help more cancer and autoimmune disease cells die when combined with TNF-α, making it a promising option for improving treatment effectiveness. This matters because it could lead to better outcomes for patients who currently struggle with the limitations of existing therapies. Who this helps: Patients with cancer and autoimmune diseases.

Plain English
This research focused on improving a new drug called CCG-203971, designed to treat fibrosis, a condition related to systemic scleroderma. The researchers created two improved versions of the drug that showed over ten times higher levels in the bloodstream of mice. One of these versions, CCG-232601, effectively reduced skin fibrosis at a lower dose than the original drug. Who this helps: This benefits patients with systemic scleroderma by offering a potential new treatment option.

Plain English
This study looked at how changes in mood, specifically sadness, affect a protein called IL-18 that is linked to inflammation in the body. Researchers found that when volunteers felt sad, their IL-18 levels increased, while a neutral mood decreased these levels. This is particularly significant in people with depression, as higher IL-18 levels can make them more susceptible to physical illnesses like diabetes and heart disease. Who this helps: This helps patients with depression by highlighting the link between mood and physical health risks.

Plain English
This study looked at how skin cells involved in blood vessel formation behave in patients with scleroderma (a condition that leads to thickening and hardening of the skin). Researchers found that these cells, while exposed to signals that typically promote new blood vessel growth, did not respond effectively. Specifically, even though certain proteins that encourage blood vessel growth were more common in the blood of scleroderma patients, the cells couldn't move toward these signals as expected, which contributes to the problems with blood flow in these patients. Who this helps: This helps patients with scleroderma by improving our understanding of their condition and potential treatment approaches.

Plain English
This study focused on a protein called Id1 produced by specific cells in the joints of people with rheumatoid arthritis (RA). Researchers discovered that activated fibroblasts in the joints are the primary source of Id1, which is linked to higher levels of inflammation. They found that Id1 not only affects blood vessel formation but is also released from these cells in tiny packages called exosomes, showing it plays a key role in the inflammation process. Who this helps: This benefits patients with rheumatoid arthritis by providing insights that could lead to new treatment strategies.

Plain English
This study looked at how certain proteins in the body, called IL-1 cytokines, interact with the brain's pain-relieving systems during a pain challenge in 34 healthy volunteers. The researchers discovered that higher levels of IL-1β in some women were linked to increased sensitivity to pain and lower availability of pain receptors in the brain. This matters because it helps explain why some people experience more pain and emotional stress, which could guide better treatments for pain and mental health conditions. Who this helps: This helps patients dealing with chronic pain, mood disorders, and substance use issues.

Plain English
This study looked at how a compound called 8-isoprostane affects blood vessel growth in patients with scleroderma, a condition that causes the skin and connective tissues to tighten and harden. Researchers found that higher levels of 8-isoprostane in patients inhibited the normal blood vessel growth process triggered by a protein called VEGF. Specifically, in lab tests, adding vitamin E, which reduces 8-isoprostane, helped restore this blood vessel growth, indicating that targeting this pathway could be important for improving treatment for scleroderma. Who this helps: This helps patients with scleroderma.

Plain English
This study looked at how a protein called Fut1 affects blood vessel growth (angiogenesis) and inflammation in a type of arthritis known as K/BxN arthritis. The researchers found that mice lacking Fut1 had less blood vessel growth and were resistant to arthritis symptoms compared to normal mice. Specifically, these Fut1-deficient mice showed a 50% reduction in angiogenesis and significantly less immune cell activity in their inflamed joints. Who this helps: This research benefits patients with rheumatoid arthritis by identifying potential targets for treatment.

Plain English
This study examined the role of an enzyme called fucosyltransferase 1 (fut1) in the tissue of patients with rheumatoid arthritis (RA). The researchers found that levels of certain fucosylated proteins were significantly higher in RA tissue than in normal tissue, and that reducing fut1 activity decreased blood vessel formation and the growth of cells involved in RA. This matters because it shows how fut1 contributes to the worsening of RA symptoms, highlighting a potential target for new treatments. Who this helps: Patients with rheumatoid arthritis.

Plain English
This study examined how a specific process in cells, known as fucosylation, affects the growth of new blood vessels in rheumatoid arthritis (RA). Researchers found that proteins with fucosylation were more abundant in RA patients, showing significant increases in a key chemokine called MCP-1 in their synovial fluid compared to those with osteoarthritis. The results indicate that blocking the fucosylation process could reduce blood vessel growth, which is crucial because excessive blood vessel formation contributes to the pain and inflammation in RA. Who this helps: This research benefits patients with rheumatoid arthritis by offering insights into potential new treatments.

Plain English
Researchers studied a protein called citrullinated epithelial neutrophil-activating peptide 78 (ENA-78/CXCL5) to see how it behaves in patients with rheumatoid arthritis (RA). They found that citrullinated ENA-78/CXCL5 levels were much higher in the blood and joint fluid of RA patients compared to healthy individuals, and its presence was closely linked to inflammation markers. This modified protein appears to help attract immune cells called monocytes to the inflamed areas of the joints, which can worsen the disease. Who this helps: This helps patients with rheumatoid arthritis by potentially improving understanding of their condition and leading to better treatments.

Plain English
This study looked at a specific protein called Fut2 and its role in blood vessel growth, which is important for healing wounds and tumor development. Researchers discovered that when Fut2 is missing in certain cells, their ability to move and form new blood vessels is significantly reduced—specifically, there was a 50% decrease in cell migration and a 60% reduction in tube formation in lab tests, compared to normal cells. Understanding how Fut2 works can help improve treatments for conditions related to poor blood vessel formation, such as chronic wounds or certain cancers. Who this helps: This helps doctors and patients dealing with wound healing and cancer treatment.

Plain English
This study looked at how a medication called certolizumab pegol, which blocks a substance called TNFα linked to rheumatoid arthritis, affects certain blood vessel cells. Researchers found that certolizumab pegol significantly reduced the activation of these cells, decreasing their ability to allow other immune cells to attach and grow new blood vessels. For example, it blocked TNFα's stimulation of adhesion molecules and other markers associated with inflammation and angiogenesis. Who this helps: This benefits patients with rheumatoid arthritis by reducing inflammation and potentially limiting disease progression.

Plain English
This study looked at how a protein called interleukin-18 (IL-18) relates to emotional responses and brain function in people with major depression (MDD) compared to healthy individuals. Researchers found that women with MDD had higher levels of IL-18 than those without (on average, 2.13 units higher), and in healthy subjects, IL-18 levels were linked to their emotional reactions. These findings are important because they suggest that IL-18 may be a marker for how well people can manage their emotions, which could help in understanding and treating depression. Who this helps: This helps patients with major depression and their doctors.

Plain English
This study looked at how green tea extract (GTE) affects certain chemical signals in cells related to rheumatoid arthritis (RA) and in a rat model of arthritis. The researchers found that GTE reduced the production of inflammatory signals (like MCP-1 and IL-8) by up to 40% in human RA cells, while also increasing the expression of their receptors in these cells. This matters because it suggests that GTE could help manage inflammation and joint damage in arthritis. Who this helps: This helps patients with rheumatoid arthritis.

Plain English
This study investigated two proteins, monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1alpha (CCL3), in patients with chronic pelvic pain syndrome, which involves ongoing pelvic pain and inflammation. The researchers found that levels of these proteins were significantly higher in patients with the inflammatory form of the condition (up to 3,261.2 pg/ml for CCL2 and 1,057.8 pg/ml for CCL3) compared to healthy controls. These findings help establish these proteins as potential biomarkers, which means they could be useful in diagnosing and possibly treating chronic pelvic pain syndrome. Who this helps: This helps patients suffering from chronic pelvic pain syndrome and healthcare providers diagnosing and managing their symptoms.

Plain English
This study looked at how a compound called epigallocatechin-3-gallate (EGCG), found in green tea, affects a substance involved in inflammation, specifically in rheumatoid arthritis (RA). The researchers found that EGCG reduced levels of a pro-inflammatory molecule called IL-6 by about 28% in the blood and 40% in the joints of rats with arthritis, while also promoting the production of a natural inhibitor that helps control inflammation. This is important because it shows that EGCG might be a useful treatment option for managing RA symptoms. Who this helps: Patients with rheumatoid arthritis.

Plain English
This study looked at a protein called Interleukin-18 (IL-18) and its effects on cells from the joint tissue of patients with rheumatoid arthritis (RA). Researchers found that IL-18 significantly increased the production of three factors that promote blood vessel growth—SDF-1alpha, MCP-1, and VEGF—showing these effects depend on specific cell signaling pathways. This finding is important because it helps us understand how inflammation in RA can lead to tissue changes that worsen the disease. Who this helps: This helps patients with rheumatoid arthritis and their doctors in understanding potential new treatment targets.

Plain English
This study looked at a protein called CXCL16 and its role in attracting immune cells to the inflamed tissue of patients with rheumatoid arthritis (RA). Researchers found that levels of CXCL16 were significantly higher in the joint fluid of RA patients, reaching up to 145 ng/ml, and this protein helps draw immune cells into the affected area, similar to the inflammatory processes triggered by another protein, TNFalpha. This is important because targeting CXCL16 and its pathways could lead to new treatments for RA, addressing inflammation more effectively. Who this helps: This benefits patients with rheumatoid arthritis by potentially offering new treatment options.

Plain English
This study looked at certain receptors on immune cells in rats with a condition similar to rheumatoid arthritis to understand how inflammation develops. Researchers found that a receptor called CCR1 was consistently present in high amounts on immune cells throughout the disease, while other receptors like CCR5 became more common as inflammation progressed. These findings are important because they can help shape new treatments that target these receptors to better manage inflammatory arthritis. Who this helps: This helps patients with inflammatory arthritis.

Plain English
This study looked at how the drug sulfasalazine (SASP) and its breakdown products affect certain proteins called chemokines in the tissue of people with rheumatoid arthritis (RA). The researchers found that when RA tissue was treated with SASP, the production of some inflammatory chemokines decreased: IL-8 levels dropped by 22%, GROalpha by 55%, and MCP-1 by 42%. This is important because lowering these chemokines may help reduce inflammation and improve symptoms in patients with RA. Who this helps: This benefits patients with rheumatoid arthritis by potentially reducing their symptoms and inflammation.

Plain English
This study looked at 104 women who had a specific genetic condition caused by balanced translocations between the X chromosome and other chromosomes. The findings showed that 42% of these women had multiple congenital abnormalities or developmental delays, which was much higher than seen in previous research. It also found that most women with gonadal dysfunction had breakpoints in a specific area of the X chromosome, while fewer cases of recognized X-linked syndromes were present than before. Who this helps: This research benefits doctors and genetic counselors working with affected women and their families.

Plain English
This study looked at two specific proteins, interleukin 8 (IL-8) and epithelial neutrophil activating peptide 78 (ENA-78), to see how they indicate inflammation in the prostate fluid of men with various prostate conditions. Researchers tested 63 men and found that IL-8 levels were significantly higher in those with bacterial prostatitis (BP), inflammatory chronic prostatitis, and asymptomatic inflammatory prostatitis compared to healthy men and those with benign prostatic hyperplasia, with IL-8 levels in BP being about 11,175 pg/mL. Understanding these measurements is important because it helps doctors identify and understand inflammation in the prostate, potentially leading to better treatments for patients with painful prostate conditions. Who this helps: This helps patients experiencing pelvic pain and doctors aiming to treat prostate-related inflammation.

Plain English
This study looked at a specific molecule called Ley/H, found in blood vessels, to understand its role in conditions like rheumatoid arthritis (RA) and its involvement in forming new blood vessels (angiogenesis). The researchers found that Ley/H levels were higher in RA patients compared to those with osteoarthritis, and it actively promotes new blood vessel formation. This is important because it could lead to new treatments for RA and other diseases where abnormal blood vessel growth is a problem. Who this helps: This helps patients with rheumatoid arthritis and doctors looking for better treatment options.

Plain English
The study explored the levels of two proteins, IL-1beta and TNF-alpha, in prostate secretions from men suffering from chronic prostatitis (CPPS) compared to healthy men and those with another condition called Benign Prostatic Hyperplasia (BPH). The researchers found that 89% of men with the more severe CPPS (CPPS IIIA) had detectable levels of IL-1beta, while only 31% of healthy controls showed similar levels; IL-1beta and TNF-alpha were more frequently found in men with CPPS compared to those with BPH or less severe forms of prostatitis. This information is important because it offers a new way to identify and manage CPPS that could lead to better treatment options, moving beyond traditional methods based solely on white blood cell counts. Who this helps: This benefits patients with chronic prostatitis and their doctors.

Plain English
This study looked at using a gene therapy technique to deliver a protein called IL-13 to reduce inflammation in the joints of people with rheumatoid arthritis. Researchers found that this therapy dramatically lowered levels of harmful substances linked to inflammation: IL-1beta was reduced by 85%, TNF-alpha by 82%, and IL-8 by up to 82% after just 48 hours. This is important because decreasing these inflammatory markers could help ease joint damage and pain in rheumatoid arthritis patients. Who this helps: This helps patients with rheumatoid arthritis.

Plain English
This study looked at how three drugs—sulfasalazine (SSZ), sulfapyridine (SP), and 5-aminosalicylic acid (5-ASA)—affect the behavior of certain cells involved in blood vessel formation, which can contribute to rheumatoid arthritis (RA). Researchers found that SSZ reduced the movement of these cells by 59% and SP by 22% when stimulated by a growth factor, while 5-ASA increased their proliferation. These findings are important because they suggest that SSZ and SP may help manage RA by slowing down unwanted blood vessel growth and inflammation. Who this helps: This helps patients with rheumatoid arthritis by potentially improving treatment options.

Plain English
This study looked at nine patients with holoprosencephaly (HPE), a brain and facial development disorder, to better understand the genetic changes linked to the condition. Researchers found a critical region on chromosome 2 that is involved in HPE and narrowed it down to less than 1 megabase, which is essential for identifying the gene responsible for this disorder. This knowledge can lead to better genetic testing and understanding of HPE, improving diagnosis and potential treatments in the future. Who this helps: This helps patients with holoprosencephaly and their families.

Plain English
This study looked at two families affected by genetic changes called translocations involving chromosomes 5 and 10. Researchers found that in one family, both a mother and son had a similar mild genetic condition due to inherited chromosome changes, while in the other family, the son showed signs of a different genetic issue linked to his mother’s balanced translocation. These findings are important because they highlight how genetic inheritance can lead to varying health impacts, indicating that certain chromosome imbalances may be less severe than previously thought. Who this helps: This helps patients and their families understand the genetic factors affecting their health.

Plain English
This study looks at a unique case where a fetus had a rare genetic condition known as maternal uniparental disomy of chromosome 9, which means both copies of that chromosome came from the mother. The researchers found that this condition was linked to an unusual placental growth issue called mosaic trisomy 9, where some cells had an extra chromosome 9. Understanding this connection is important because it helps explain how certain genetic disorders can develop during pregnancy. Who this helps: This information benefits doctors and genetic counselors in understanding and managing similar cases.

Plain English
This study tested a new method for quickly preparing and analyzing perinatal tissue samples, which are collected around the time of birth. With the new technique, researchers reduced the time needed to culture tissue from an average of 17 days to just 8.7 days and improved the success rate of obtaining usable samples from 76% to 88%. This matters because faster and more reliable analysis can help diagnose conditions more quickly, leading to better patient care. Who this helps: Patients who need timely diagnostic results and their doctors.

Plain English
In this study, researchers investigated a protein called EEA1, which is important for the transport of materials within cells. They found that EEA1 is located in early endosomes, where it helps sort and direct substances to their correct destinations. Specifically, they noted that EEA1 plays a key role in moving proteins through early endosomes, and its unique structure, including special "finger" motifs, is crucial for this function. Who this helps: This helps patients with conditions affected by cellular transport issues, as understanding EEA1 could lead to better treatments.

Plain English
This study examined how a specific part of the RPTP beta protein interacts with another protein called contactin, which is found on the surface of nerve cells. The researchers discovered that this interaction promotes nerve cell adhesion and growth, highlighting that the carbonic anhydrase domain of RPTP beta effectively acts as a signaling partner for contactin. Understanding this interaction is important because it helps clarify how nerve cells communicate and grow, which can inform treatments for nerve injuries or developmental disorders. Who this helps: This research benefits patients with nerve injuries or developmental neurological conditions.